Grape King Bio's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 11.34.
Grape King Bio's Days Inventory for the
three
months ended in Dec. 2025 was 107.06.
Grape King Bio's Days Payable for the
three
months ended in Dec. 2025 was 48.17.
Therefore, Grape King Bio's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 70.23.
Grape King Bio (TPE:1707) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Grape King Bio Cash Conversion Cycle Related Terms
Grape King Bio Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1707 vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Grape King Bio's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a Cash Conversion Cycle of 70.23 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Grape King Bio and its competitors.
Is Grape King Bio's Cash Conversion Cycle too high?
Grape King Bio's current Cash Conversion Cycle is 70.23. The Drug Manufacturers industry median Cash Conversion Cycle is 145.87. Grape King Bio's value of 70.23 is 51.9% below this industry median. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Cash Conversion Cycle compare to ZTS and UTHR?
Grape King Bio's Cash Conversion Cycle of 70.23 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.87. Grape King Bio's value of 70.23 is 51.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.87, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Cash Conversion Cycle of 70.23 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Cash Conversion Cycle is 70.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.04, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current Cash Conversion Cycle is 70.23 and 51.9% below the Drug Manufacturers industry median of 145.87. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Cash Conversion Cycle is 70.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.04.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
Cash Conversion Cycle: 70.23
GF Value™: NT$144.04 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 51.9% below the Drug Manufacturers median
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
